Table 3.
Univariable and multivariable relapse‐free survival analyses.
| Relapse‐free survival (Events/Pts = 68/87) | Univariable | Multivariable | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | Adjusted HR (95% CI) | P value | P value (LR test) | |
| PIK3α | |||||
| Low | 1 | 1 | 0·003 | ||
| High | 1·87 (1·02–3·45) | 0·04 | 3·07 (1·53–6·17) | 0·002 | |
| Gender | |||||
| Female | 1 | 1 | 0·01 | ||
| Male | 1·86 (1·06–3·29) | 0·03 | 2·16 (1·16–4·05) | 0·02 | |
| ECOG | |||||
| 0–1 | 1 | 1 | <0·001 | ||
| 2–4 | 8·81 (3·45–22·48) | <0·001 | 11·33 (3·96–32·42) | <0·001 | |
| Unknown | 1·44 (0·81–2·57) | 0·2 | 2·16 (1·06–4·38)* | 0·03 | |
| Stage | |||||
| I–II | 1 | 1 | 0·005 | ||
| III–IV | 1·57 (0·93–2·67) | 0·09 | 2·16 (1·23–3·78) | 0·007 | |
| Anthracycline‐based chemo in first line | |||||
| No | 1 | 1 | <0·001 | ||
| Yes | 0·41 (0·24–0·68) | 0·001 | 0·22 (0·12–0·41) | <0·001 | |
| Unknown | 0·40 (0·12–1·36)* | 0·1 | 0·42 (0·11–1·55)* | 0·2 | |
| Age at diagnosis | |||||
| ≤60 | 1 | ||||
| >60 | 1·57 (0·96–2·56) | 0·07 | |||
| IPI score | |||||
| Low (0–2) | 1 | ||||
| High (3–5) | 2·28 (1·31–3·97) | 0·004 | |||
| Not evaluated | 1·75 (0·92–3·32) | 0·09 | |||
| Disease type | |||||
| Non‐NKTCL | 1 | ||||
| NKTCL | 1·69 (0·96–2·97) | 0·07 | |||
| Elevated LDH | |||||
| No | 1 | ||||
| Yes | 1·94 (0·98–3·83) | 0·06 | |||
| Unknown | 1·41 (0·44–4·54) | 0·6 | |||
| PIK3δ | |||||
| Low | 1 | ||||
| High | 0·59 (0·36–0·97) | 0·04 | |||
| PIK3β | |||||
| Negative | 1 | ||||
| Positive | 0·73 (0·35–1·54) | 0·4 | |||
| PIK3γ | |||||
| Negative | 1 | ||||
| Positive | 1·09 (0·67–1·77) | 0·7 | |||
| PTEN | |||||
| Low | 1 | ||||
| High | 0·67 (0·27–1·68) | 0·4 | |||
P value calculated using Wald test or likelihood ratio test (indicated by LR test). ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; NKTCL, natural killer/T‐cell lymphoma; LDH, lactate dehydrogenase.
*
Proportional hazard assumption violated.